

LBT CHAIR APPOINTMENT

Experienced medical technology Non-Executive Director Rebecca Wilson appointed Chair

Adelaide, Australia, 03 July 2023: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in microbiology automation using artificial intelligence, is pleased to announce the appointment of Ms Rebecca Wilson, a highly experienced medical technology Non-Executive Director as Chair of the Board, effective immediately.

Key Points:

- **Ms Wilson appointed Chair, succeeding Joanne Moss who advised her retirement in May.**
- **Ms Wilson has been a consultant to Boards and Executive Teams in the MedTech sector for more than 25 years.**
- **She is currently the Chair of Alcidion Group (ASX ALC), a position she's held since 2019, and NED of UK health and wellness business Ateria Health.**

Melbourne based Ms Wilson brings more than 25 years' experience in the MedTech sector as both an executive advisor and Non-Executive Director. She is highly regarded for her expertise in governance and risk management, issues and crisis management, investor relations, ESG, and complex stakeholder communication.

She has a deep network of professional investors in Australia, New Zealand, Asia, United Kingdom, and United States.

Ms Wilson joined the board of digital health business Alcidion (ASX ALC) in 2017, succeeding to Chair in 2019. Under her stewardship, Alcidion has achieved substantial growth and scale in international markets and executed an active acquisition program which resulted in the completion of two globally significant acquisitions in the last two years.

Ms Wilson is also a Non-Executive Director of UK private health and wellness company Ateria Health.

Commenting on her appointment Ms Wilson said:

"The convergence of technology and healthcare is profoundly important to addressing the significant challenges faced by the industry today. Workforce shortages have been well documented and the introduction of automation to laboratory workflows is helping laboratories globally meet current testing demand whilst also improving the speed and accuracy of specimen testing that ultimately improves diagnosis and better informs patient treatment."

"I'm pleased to be joining LBT at a time where the foundations are in place to drive stronger sales execution. LBT's APAS® PharmaQC and APAS® Clinical products are proven technologies, with international regulatory approvals in place, and top tier partnerships established with both Thermo Fisher and AstraZeneca."

LBT announced in May 2023 the retirement of Joanne Moss as Chair due to increasing professional work commitments. She concluded her role as Non-Executive Chair on 30th June 2023, and will remain available as required.

LBT Managing Director and CEO, Mr Brent Barnes added:

"Rebecca is a well-respected and recognised leader within the MedTech ecosystem and someone I've known and admired for several years. Her experience and industry connections add meaningful bench strength to our Company at an important time. I welcome her hands-on management approach and expect immediate focus on near-term priorities for the Company."

On behalf of the Board, I'd also like to thank Joanne for her contributions to the Company over the last two years, that has delivered a solid foundation for potential future growth."

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company's second product, the Automated Plate Assessment System (APAS® Independence) uses LBT's intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

| |
|---|
| LBT Innovations |
| Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com |